Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) saw unusually-high trading volume on Friday . Approximately 5,660,859 shares changed hands during trading, an increase of 267% from the previous session’s volume of 1,540,955 shares.The stock last traded at $11.26 and had previously closed at $9.90.
IRWD has been the subject of a number of research reports. JPMorgan Chase & Co. raised Ironwood Pharmaceuticals from an “underweight” rating to a “neutral” rating and increased their price target for the company from $11.00 to $13.00 in a research note on Thursday, January 24th. BidaskClub lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. Zacks Investment Research raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 28th. Wood & Company reissued a “buy” rating on shares of Ironwood Pharmaceuticals in a research note on Thursday, January 31st. Finally, ValuEngine raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Ironwood Pharmaceuticals has an average rating of “Hold” and an average target price of $15.15.
The company has a market cap of $1.74 billion, a PE ratio of -11.85 and a beta of 1.89.
In other news, CFO Gina Consylman sold 5,677 shares of the firm’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $14.31, for a total value of $81,237.87. Following the completion of the sale, the chief financial officer now directly owns 168,543 shares of the company’s stock, valued at approximately $2,411,850.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark G. Currie sold 275,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $13.26, for a total value of $3,646,500.00. Following the completion of the sale, the insider now directly owns 577,980 shares of the company’s stock, valued at $7,664,014.80. The disclosure for this sale can be found here. Insiders sold a total of 288,376 shares of company stock valued at $3,822,783 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.
Large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY raised its holdings in shares of Ironwood Pharmaceuticals by 330.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 44,771 shares of the biotechnology company’s stock worth $464,000 after buying an additional 34,372 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Ironwood Pharmaceuticals by 22.8% in the fourth quarter. Two Sigma Advisers LP now owns 43,157 shares of the biotechnology company’s stock worth $447,000 after buying an additional 8,000 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Ironwood Pharmaceuticals by 5.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,974,879 shares of the biotechnology company’s stock worth $20,460,000 after buying an additional 96,070 shares during the period. CWM LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $31,000. Finally, Nomura Holdings Inc. increased its holdings in Ironwood Pharmaceuticals by 30.6% during the 4th quarter. Nomura Holdings Inc. now owns 66,622 shares of the biotechnology company’s stock worth $688,000 after purchasing an additional 15,614 shares during the period. 97.04% of the stock is owned by institutional investors and hedge funds.
WARNING: This story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/19/ironwood-pharmaceuticals-irwd-sees-unusually-high-trading-volume.html.
About Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
See Also: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.